Urinary disturbances in patients with 142 diabetes


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The significance of diabetes is not only due to its high prevalence, but also to its serious complications. Urinary disturbances, which are referred as diabetic cystopathy, are among the most common complications of diabetes. The current data on the prevalence, manifestations, and possible pathogenesis of diabetic cystopathy are presented in the review of literature.

Full Text

Restricted Access

About the authors

Z. K Gadzhieva

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: zgadzhieva@ooorou.ru
MD, urologist at the UKB №2 of I.M. Sechenov First Moscow State Medical University of Ministry of Public Health of the Russian Federation (Sechenov University)., scientific editor of Journal «Urologiia», Deputy Director of ROU for work with regions Moscow, Russia

E. A Atamanova

AO “Astellas Pharma”

Email: Ekaterina.atamanova@astellas.com
MD, PhD, Medical Advisor Moscow, Russia

K. R Khamidullin

Republic of Bashkortostan City Clinical Hospital No. 21

Email: Kamil.urolog@gmail.com
doctor of urology Department Ufa, Russia

A. M Pushkarev

G.G. Kuvatov Republican Clinical Hospital

Email: Pushkar967@yandex.ru
Dr.Med.Sci., Prof., Head of the Department of Urology Ufa, Russia

References

  1. https://doctorpiter.ru/diseases/54/
  2. Cowie C.C., Rust K.F., Byrd-Holt D.D., Eberhardt M.S., Flegal K.M., Engelgau M.M., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263. [PubMed: 16732006].
  3. Brown J.S., Vittinghoff E., Lin F., Nyberg L.M., Kusek J.W., Kanaya A.M. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001 -2002. Diabetes Care 2006;29:1307. [PubMed: 16732013]
  4. Shabudina N.O. Clinical manifestations and treatment of urinary disturbances in patients with type II diabetes. Avtoref. dis. kand. med. nauk, 2014. Russian (Шабудина Н.О. Клиническое течение и лечение нарушений мочеиспускания у больных сахарным диабетом 2 типа. Автореф. дисс. канд. мед. наук, 2014).
  5. Остроухова E.H. Выявление и лечение сахарного диабета 2 типа - проблема междисциплинарная. Проблемы эндокринологии. 2013;59(1):44-48).
  6. Сунцов Ю.И., Болотская Л.Л., Маслова О.В., Казаков И.В. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации. Сахарный диабет. 2011;1:15-18.)
  7. Whiting D.R., Guariguata L, Weil C., Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321.
  8. Frimodt-Meller C. Diabetic cystopathy. A review of the urodynamic and clinical features of neurogenic bladder dysfunction in diabetes mellitus. Dan Med Bull 1978;25:49-60.
  9. Lee W.C., Wu H.P., Tai T.Y., Liu S.P., Chen J., Yu H.J. Effects of diabetes on female voiding behavior. J Urol 2004;172:989-992.
  10. Kebapci N., Yenilmez A., Efe B., Entok E., Demirustu C. Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn 2007;26:814-819.
  11. Frimodt-Meller C. Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med. 1980;92(2 Pt 2):318-321.
  12. Kaplan S.A., Te A.E., Blaivas J.G. Urodynamic ndings in patients with diabetic cystopathy. J Urol 1995;153:342-344.
  13. Brown J. S. Diabetic cystopathy - what does it mean? J. Urol. 2009;181(1):13-14.
  14. Yoshimura N., Chancellor M.B., Andersson K.E. Recent ad vances in understanding the biology of diabetesassociated blad der complications and novel therapy. BJU Int. 2005;95:733-738.
  15. Аль-Шукри С.Х., Кузьмин И.В., Шабудина Н.О. Дисфункции нижних мочевых путей у больных сахарным диабетом. Уральский медицинский журнал. 2012;3:114-119).
  16. Hill S R, Fayyad A M, Jones G R. Diabetes mellitus and female lower urinary tract symptoms: a review. Neurourol. Urodyn. 2008;27(5):362-367.
  17. Ueda T., Yoshimura N., Yoshida O. Diabetic cystopathy: re lationship to autonomic neuropathy detected by sympathetic skin response. J. Urol. (Baltimore). 1997;157(2):580-584.
  18. Hunter K.F., Moore K.N. Diabetesassociated bladder dys function in the older adult. Geriatr. Nurs. 2003;24:138-145.
  19. Аль-Шукри С.Х., Кузьмин И.В., Шабудина Н.О. Состояние уродинамики нижних мочевых путей у больных с диабетической цистопатией. Урологические ведомости. 2012;4).
  20. McGrother C.W., Donaldson M.M.K. et al. Etiology of overactive bladder: A diet and lifestyle model for diabetes and obesity in older women. Neurourol. Urodyn. 2012; 31(4): 487-495.
  21. Ripoli A., Palleschi G., Pastore A.L. et al. Overactive bladder in diabetes mellitus patients: a questionnaire based observational investigation. Neurourol Urodyn. 2013;32(6):592-593.
  22. Wen J.G., Huang C.X., Li Z.Z. et al. The effect of diabetes duration on voiding function in people more than 45 year old. Neurourol Urodyn. 2013;32(6):848.
  23. Kuz'min I.V., Shabudina N.O. The epidemiology and risk factors of urinary disturbances in patients with diabetes. Urologija. 2014;6:114-118. Russian (Кузьмин И.В., Шабудина Н.О. Эпидемиология и факторы риска развития нарушений мочеиспускания у больных сахарным диабетом. Урология. 2014;6:114-118).
  24. Yuan Z, Tang Z., He C., Tang W. Diabetic cystopathy: A review. J Diabetes 2015;7:442-447.
  25. Saito M., Nakamura I., Miyagawa I. Autoradiographic localization of muscarinic receptors in diabetic rat bladder. Nihon Hinyokika Gakkai Zasshi 1997;88:858-867.
  26. Tong Y.C., Chin W.T., Cheng J.T. Alterations in urinary bladder M2-muscarinic receptor protein and mRNA in 2-week streptozotocin-induced diabetic rats. Neurosci Lett 1999;277:173-176.
  27. Daneshgari F., Liu G., Imrey P.B. Time dependent changes in diabetic cystopathy in rats include compensated and decompensated bladder function. J Urol 2006;176:380-386.
  28. Wu L., Zhang X., Xiao N., Huang Y., Kavran M., Elrashidy R.A., et al. Functional and morphological alterations of the urinary bladder in type 2 diabetic FVB(db/db) mice. J Diabetes Complications 2016;30:778-785.
  29. Be shay E., Carrier S. Oxidative stress plays a role in diabetes-induced bladder dysfunction in a rat model. Urology 2004;64:1062-1067.
  30. Changolkar A.K., Hypolite J.A., Disanto M., Oates P.J., Wein A.J., Chacko S. Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J Urol 2005;173:309-313.
  31. Nakamura N., Obayashi H., Fujii M., Fukui M., Yoshimori K., Ogata M., et al. Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic Biol Med 2000;29:17-25.
  32. Daneshgari F., Liu G., Birder L., Hanna-Mitchell A. T., Chacko S. Diabetic bladder dysfunction: Current translational knowledge. J Urol 2009;182:S18-26.
  33. Steinberg S.F. Oxidative stress and sarcomeric proteins. Circ Res 2013;112:393-405.
  34. Yohannes E., Chang J., Christ G.J., Davies K.P., Chance M.R. Proteomics analysis identi es molecular targets related to diabetes mellitus-associated bladder dysfunction. Mol Cell Proteomics 2008;7:1270-1285.
  35. Gandhi J., Dagur G., Warren K., Smith N.L., Khan S.A. Genitourinary complications of diabetes mellitus: An overview of pathogenesis, evaluation, and management. Curr Diabetes Rev. 2017;13:498-518.
  36. Tong Y.C., Cheng J.T., Hsu C.T. Alterations of M(2)-muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocin-induced diabetic rat urinary bladder. Neurosci Lett 2006;406:216-221.
  37. Golbidi S., Laher I. Bladder dysfunction in diabetes mellitus. Front Pharmacol 2010;1:136.
  38. Pinna C., Zanardo R., Puglisi L. Prostaglandin-release impairment in the bladder epithelium of streptozotocin-induced diabetic rats. Eur J Pharmacol 2000;388:267-273.
  39. Pitre D.A., Ma T., Wallace L.J., Bauer J.A. Time-dependent urinary bladder remodeling in the streptozotocin-induced diabetic rat model. Acta Diabetol 2002;39:23-27.
  40. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002;113(Suppl. 1A):80S-4S.
  41. Jackson S. The patient with an overactive bladder - symptoms and quality of life issues. Urology. 1997;57(6A):18-22.
  42. Abrams P., Kelleher C.J., Kerr L.A., Rogers R.G. Overactive bladder significantly affects quality of life. Am. J. Manag. Care. 2000;6:580-590.
  43. Аль-Шукри С.Х., Кузьмин И.В. Качество жизни больных с гиперактивностью мочевого пузыря. Урологические ведомости. 2011;1(1):21-26).
  44. Кузьмин И.В., Шабудина Н.О. Оценка качества жизни больных с диабетической и идиопатической гиперактивностью мочевого пузыря. Урологические ведомости. 2014;IV(1):11-14).
  45. EAU Guidelines, 2019. Доступно на www.uroweb.org
  46. Khullar V. et al. Efficacy and tolerability of mirabegron, a |3(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63(2):283-95.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies